These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 34524579)

  • 21. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
    Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
    Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process.
    Wang HY; Liu YN; Wu SG; Hsu CL; Chang TH; Tsai MF; Lin YT; Shih JY
    Cancer Biomark; 2020; 28(3):351-363. PubMed ID: 32417760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
    Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
    Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis.
    Zhao M; Ang L; Huang J; Wang J
    Tumour Biol; 2017 Feb; 39(2):1010428317691682. PubMed ID: 28222665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
    Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
    Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
    Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
    Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA as Regulators of Cancer Stem Cells and Chemoresistance in Colorectal Cancer.
    Liu X; Fu Q; Du Y; Yang Y; Cho WC
    Curr Cancer Drug Targets; 2016; 16(9):738-754. PubMed ID: 26577538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
    Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
    Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance.
    Mutlu M; Raza U; Saatci Ö; Eyüpoğlu E; Yurdusev E; Şahin Ö
    J Mol Med (Berl); 2016 Jun; 94(6):629-44. PubMed ID: 27094812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer.
    Ward A; Balwierz A; Zhang JD; Küblbeck M; Pawitan Y; Hielscher T; Wiemann S; Sahin Ö
    Oncogene; 2013 Feb; 32(9):1173-82. PubMed ID: 22508479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crosstalk between TGF-β signaling and miRNAs in breast cancer metastasis.
    Chen W; Zhou S; Mao L; Zhang H; Sun D; Zhang J; Li J; Tang JH
    Tumour Biol; 2016 Aug; 37(8):10011-9. PubMed ID: 27153853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
    Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
    J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EMT-associated microRNAs and their roles in cancer stemness and drug resistance.
    Pan G; Liu Y; Shang L; Zhou F; Yang S
    Cancer Commun (Lond); 2021 Mar; 41(3):199-217. PubMed ID: 33506604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling.
    Yin Y; Wang X; Li T; Ren Q; Li L; Sun X; Zhang B; Wang X; Han H; He Y; Cao Z; Sun X; Zhou Z
    Cancer Med; 2020 Feb; 9(4):1544-1552. PubMed ID: 31899608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
    Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
    Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network.
    Haga CL; Phinney DG
    J Biol Chem; 2012 Dec; 287(51):42695-707. PubMed ID: 23105110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
    Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
    Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications.
    Tian W; Chen J; He H; Deng Y
    Clin Transl Oncol; 2013 May; 15(5):335-42. PubMed ID: 22914907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long noncoding RNA AC073284.4 suppresses epithelial-mesenchymal transition by sponging miR-18b-5p in paclitaxel-resistant breast cancer cells.
    Wang YY; Yan L; Yang S; Xu HN; Chen TT; Dong ZY; Chen SL; Wang WR; Yang QL; Chen CJ
    J Cell Physiol; 2019 Dec; 234(12):23202-23215. PubMed ID: 31215650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer.
    Najjary S; Mohammadzadeh R; Mokhtarzadeh A; Mohammadi A; Kojabad AB; Baradaran B
    Gene; 2020 May; 738():144453. PubMed ID: 32035242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.